Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement
bdtonline.com
news
2022-10-19 10:32:36

Merger brings U.S. management and presence, cash to develop compelling late-stage assetLead candidate AL102being evaluatedinongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors AyalaandAdvaxisstockholderswillrespectivelyownapproximately62.5%and37.5%Combined Company to SeekUplistingto NasdaqConference Call and Webcast today at8:00amETREHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Â Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA) (Ayala), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers and Advaxis, Inc.
